FDA spurns Lilly, Boehringer diabetes drug, cites factory problem
March 5 (Reuters) - Eli Lilly and Co and partner Boehringer Ingelheim said U.S. regulators have declined to approve their experimental diabetes drug empagliflozin, citing previously observed deficiencies at a manufacturing facility where it would be made.
The drugmakers, in a joint release on Wednesday, said the U.S. Food and Drug Administration determined that deficiencies at the Boehringer Ingelheim factory would have to be resolved before the product could be approved.
- Islamic State threat 'beyond anything we've seen': Pentagon
- Oklahoma City policeman arrested for raping women while on patrol
- Islamic State threat 'beyond anything we've seen': Pentagon |
- Ukraine accuses Russia of invasion after aid convoy crosses border |
- Exclusive: Apple iPhone 6 screen snag leaves supply chain scrambling